文献速递泌尿生殖与妇科肿瘤放疗

功能影像引导的立体定向消融体部放疗(SABR)联合局灶剂量递增与膀胱三角区保护治疗中高危前列腺癌:II期safo试验研究方案

Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
PubMed 文献 · Radiat Oncol · 2024-05-03

本II期试验旨在评估MRI引导下前列腺SABR联合局灶剂量递增(全腺体36.25 Gy/5次,索引病灶同步补量至50 Gy/5次)并保护膀胱三角区和尿道,治疗中高危局限性前列腺癌的疗效、安全性和生活质量影响,主要终点为生化控制(Phoenix标准)和局部控制(治疗后MRI)。

要点

  • 中高危前列腺癌患者接受SABR 36.25 Gy/5次,索引病灶同步补量至50 Gy/5次,并保护膀胱三角区和尿道。
  • 采用每日CBCT和前列腺内金标实现分次内运动监测,允许使用雄激素剥夺治疗(ADT)。
  • 主要终点为生化控制(Phoenix标准)和局部控制(治疗后MRI),次要终点包括急慢性毒性、生活质量和无进展生存。

核心结论

  • 据作者所知,这是首个评估治疗后MRI对接受SABR和MRI引导局灶剂量递增的中高危前列腺癌患者局部控制影响的试验。
  • 试验结果将增进对SABR技术在此特定患者亚组(尤其高危患者)中实施局灶剂量递增的理解,并有助于阐明MRI在监测局部反应中的意义。
  • 作者希望该试验有助于在此特定背景下设计更个性化的基于生物标志物的III期试验,并预期该试验将被纳入一项聚焦于接受放疗的局限性前列腺癌的前瞻性影像组学研究。

研究设计与样本

  • II期试验,纳入根据NCCN定义的中危和高危局限性前列腺癌患者。
  • 治疗方案:全前列腺SABR 36.25 Gy分5次,MRI引导下对索引病灶同步整合补量至50 Gy分5次,采用保护膀胱三角区和尿道的方案。
  • 分次内运动监测采用每日锥形束CT(CBCT)和前列腺内金标的分次内追踪,允许使用雄激素剥夺治疗(ADT)。
  • 主要终点为生化控制和局部控制,分别采用Phoenix标准和处理后MRI评估;次要终点包括急性和晚期毒性、生活质量和无进展生存。
  • 高危患者亚组将参与一项聚焦于免疫表型分析的前瞻性研究。

关键数值与推荐

  • SABR剂量:全前列腺36.25 Gy分5次,索引病灶同步整合补量至50 Gy分5次。
  • 主要终点评估:生化控制采用Phoenix标准,局部控制采用治疗后MRI。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment alternative for patients with localized low and intermediate risk prostate cancer patients. As already explored by some authors in the context of conventional moderate hypofractionated radiotherapy, focal boost of the index lesion defined by magnetic resonance imaging (MRI) is associated with an improved biochemical outcome. The objective of this phase II trial is to determine the effectiveness (in terms of biochemical, morphological and functional control), the safety and impact on quality of life, of prostate SABR with MRI guided focal dose intensification in males with intermediate and high-risk localized prostate cancer. METHODS: Patients with intermediate and high-risk prostate cancer according to NCCN definition will be treated with SABR 36.25 Gy in 5 fractions to the whole prostate gland with MRI guided simultaneous integrated focal boost (SIB) to the index lesion (IL) up to 50 Gy in 5 fractions, using a protocol of bladder trigone and urethra sparing. Intra-fractional motion will be monitored with daily cone beam computed tomography (CBCT) and intra-fractional tracking with intraprostatic gold fiducials. Androgen deprivation therapy (ADT) will be allowed. The primary endpoint will be efficacy in terms of biochemical and local control assessed by Phoenix criteria and post-treatment MRI respectively. The secondary endpoints will encompass acute and late toxicity, quality of life (QoL) and progression-free survival. Finally, the subgroup of high-risk patients will be involved in a prospective study focused on immuno-phenotyping. DISCUSSION: To the best of our knowledge, this is the first trial to evaluate the impact of post-treatment MRI on local control among patients with intermediate and high-risk prostate cancer undergoing SABR and MRI guided focal intensification. The results of this trial will enhance our understanding of treatment focal intensification through the employment of the SABR technique within this specific patient subgroup, particularly among those with high-risk disease, and will help to clarify the significance of MRI in monitoring local responses. Hopefully will also help to design more personalized biomarker-based phase III trials in this specific context. Additionally, this trial is expected to be incorporated into a prospective radiomics study focused on localized prostate cancer treated with radiotherapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT05919524; Registered 17 July 2023. TRIAL SPONSOR: IRAD/SEOR (Instituto de Investigación de Oncología Radioterápica / Sociedad Española de Oncología Radioterápica). STUDY SETTING: Clinicaltrials.gov identifier: NCT05919524; Registered 17 July 2023. TRIAL STATUS: Protocol version number and date: v. 5/ 17 May-2023. Date of recruitment start: August 8, 2023. Date of recruitment completion: July 1, 2024.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zapatero A, Castro P, Roch M, et al. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial. Radiat Oncol. 2024. PMID: 38702761. doi:10.1186/s13014-024-02440-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。